
ACS Omega, Journal Year: 2024, Volume and Issue: 9(29), P. 31586 - 31600
Published: July 12, 2024
This study endeavors to develop an injectable subdermal implant material tailored for soft tissue repair and enhancement. The consists of a ceramic phase calcium hydroxyapatite (CaHA), which is biocompatible, 20–60 μm in size, known its biocompatibility minimal likelihood causing foreign body reactions, antigenicity, inflammatory response, dispersed carrier composed carboxymethyl cellulose (CMC), glycerol, water injection. gel formulation underwent comprehensive characterization via various analytical techniques. X-ray diffraction (XRD) was employed identify crystalline phases investigate the structural properties particles, while thermogravimetric analysis (TGA) conducted evaluate thermal stability decomposition behavior final formulation. Scanning electron microscopy (SEM) utilized examine surface morphology particle size distribution, confirming homogeneous dispersion spherical CaHA particles within matrix. SEM revealed sizes ranging from approximately μm. Elemental confirmed stoichiometric Ca/P ratio 1.65 (HA) structure. Heavy metal content exhibited suitability surgical use without posing toxicity risks. Rheological storage modulus 58.6 68.9 kPa loss 21.7 24.8 at frequencies 2 5 Hz, respectively. 150 μL sterilized CaHA/CMC injected subcutaneously into rats compared with similar product, Crystalys, assess effects on tissues. Skin samples were collected specific intervals throughout (30, 45, 60, 90 120 days), examined histologically. Results demonstrated that led significant increase dermal thickness, elastic fibers, collagen density. Based findings, formulated found be biodegradable, nonimmunogenic, nontoxic, safe, effective, represents promising option augmentation.
Language: Английский